相似文献
1
Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome.
Blood Cancer J. 2024 Nov 11;14(1):200. doi: 10.1038/s41408-024-01181-w.
2
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.
3
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.
4
5
[Clonal diseases in the border zone rheumatology/hematology].
Z Rheumatol. 2025 Jul 9. doi: 10.1007/s00393-025-01678-0.
6
The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy.
Kidney Int. 2025 May 20. doi: 10.1016/j.kint.2025.04.018.
7
Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.
JNCI Cancer Spectr. 2024 Nov 1;8(6). doi: 10.1093/jncics/pkae095.
8
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21.
9
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25.
10
Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.
Haematologica. 2014 Dec;99(12):1846-53. doi: 10.3324/haematol.2014.111104. Epub 2014 Sep 5.
本文引用的文献
1
Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.
Sci Adv. 2022 Apr 8;8(14):eabl6579. doi: 10.1126/sciadv.abl6579. Epub 2022 Apr 6.
2
Association between telomere length and mitochondrial copy number and cancer risk in humans: A meta-analysis on more than 300,000 individuals.
Crit Rev Oncol Hematol. 2021 Nov;167:103510. doi: 10.1016/j.critrevonc.2021.103510. Epub 2021 Oct 22.
3
Polygenic basis and biomedical consequences of telomere length variation.
Nat Genet. 2021 Oct;53(10):1425-1433. doi: 10.1038/s41588-021-00944-6. Epub 2021 Oct 5.
4
Genetically determined telomere length and multiple myeloma risk and outcome.
Blood Cancer J. 2021 Apr 14;11(4):74. doi: 10.1038/s41408-021-00462-y.
5
Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.
Blood Cancer J. 2020 Sep 1;10(8):89. doi: 10.1038/s41408-020-00356-5.
6
Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.
Blood Adv. 2020 Jun 23;4(12):2789-2797. doi: 10.1182/bloodadvances.2020001435.
7
Multiple myeloma.
Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46.
8
Mutations, Cancer and the Telomere Length Paradox.
Trends Cancer. 2017 Apr;3(4):253-258. doi: 10.1016/j.trecan.2017.02.005. Epub 2017 Mar 27.
9
Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.
Front Med. 2016 Jun;10(2):191-203. doi: 10.1007/s11684-016-0450-2. Epub 2016 May 16.
10
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.
Int J Cancer. 2015 Mar 1;136(5):E351-8. doi: 10.1002/ijc.29101. Epub 2014 Aug 6.
Zotero 插件